Skip to Content

GlycoMimetics Inc GLYC

Morningstar Rating
$3.05 −0.13 (4.09%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GLYC is trading at a 49% discount.
Price
$2.84
Fair Value
$2.22
Uncertainty
Extreme
1-Star Price
$18.80
5-Star Price
$9.16
Economic Moat
Lybp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLYC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.18
Day Range
$2.913.06
52-Week Range
$1.123.35
Bid/Ask
$3.01 / $3.07
Market Cap
$194.47 Mil
Volume/Avg
282,417 / 327,807

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
39

Comparables

Valuation

Metric
GLYC
SWTX
ATXS
Price/Earnings (Normalized)
Price/Book Value
4.405.883.78
Price/Sales
580.59
Price/Cash Flow
Price/Earnings
GLYC
SWTX
ATXS

Financial Strength

Metric
GLYC
SWTX
ATXS
Quick Ratio
7.766.2121.34
Current Ratio
8.146.4121.73
Interest Coverage
Quick Ratio
GLYC
SWTX
ATXS

Profitability

Metric
GLYC
SWTX
ATXS
Return on Assets (Normalized)
−59.22%−39.61%−23.26%
Return on Equity (Normalized)
−67.86%−45.43%−44.07%
Return on Invested Capital (Normalized)
−70.86%−49.28%−28.94%
Return on Assets
GLYC
SWTX
ATXS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRyqhpmtjPzjm$571.0 Bil
VRTX
Vertex Pharmaceuticals IncSdzrjyfGkpxps$107.8 Bil
REGN
Regeneron Pharmaceuticals IncPxvmrmpwDmxblqh$106.1 Bil
MRNA
Moderna IncTcyxhfptHcwg$42.3 Bil
ARGX
argenx SE ADRPvcdclfpvDzhzw$23.7 Bil
BNTX
BioNTech SE ADRVmdlytdVlkjz$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncDjjjwbrrLtxsgcx$19.4 Bil
BMRN
Biomarin Pharmaceutical IncDwffxvyJgbjsbn$16.7 Bil
RPRX
Royalty Pharma PLC Class AYlnccnycvWhxbtp$13.6 Bil
INCY
Incyte CorpRzbysvfNmpdr$12.8 Bil

Sponsor Center